Key facts
- Alzheon’s last known valuation is $550.0M (Apr 2022).
- It has raised $212.2M across 9 recorded rounds; the latest was Later Stage VC ($126.3M) in Feb 2024.
- Notable investors include Ally Bridge Group, HCL Capital, Alerce Investment Management, Aptorum Group, Ron Sachs — 8 tracked in total.
- Alzheon has filed 14 Form Ds with the SEC since 2013, most recently Feb 2025 ($126.3M sold to 76 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 9 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Alzheon
Funding rounds
9 roundsAbout Alzheon
Developer of a small molecule-based drug discovery platform designed to treat Alzheimer's disease and other neurodegenerative disorders. The company's platform specializes in the development of oral inhibitors of amyloid neurotoxicity by inhibiting protein misfolding and aggregation based on individual genetic and biological information, enabling the healthcare industry to treat neurological disorders efficiently.
- Sector
- Healthcare
- HQ
- Framingham, MA, United States
- Founded
- 2013
- Employees
- 32
- Website
- alzheon.com/
- Ownership
- Privately Held (backing)
Alzheon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alzheon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alzheon in its N-PORT filings yet. We sweep new filings monthly.